Lynn E DeLisi1. 1. New York University, New York, NY 10016, USA. delisi76@aol.com
Abstract
PURPOSE OF REVIEW: This review explores what is known about the association of cannabis with schizophrenia, its effects on the brain, and whether the brain changes known to be present in schizophrenia could be caused by cannabis and thus lead to a psychosis. RECENT FINDINGS: The heavy use of cannabis is known to be associated with some adverse consequences, such as the occurrence of acute psychotic episodes and the development of chronic schizophrenia in some people even after its use has terminated. Recent studies have produced controversy about whether cannabis in heavy use can cause irreversible brain damage, particularly to adolescents, and thus whether a chronic psychosis could be a result of brain changes caused by cannabis. SUMMARY: From the evidence that exists, it appears that the above view is unlikely and that cannabis may even have benign effects on brain structure, not producing deleterious damage. Its neurochemical interactions with the dopaminergic pathway, however, may, particularly in genetically vulnerable individuals, have adverse consequences.
PURPOSE OF REVIEW: This review explores what is known about the association of cannabis with schizophrenia, its effects on the brain, and whether the brain changes known to be present in schizophrenia could be caused by cannabis and thus lead to a psychosis. RECENT FINDINGS: The heavy use of cannabis is known to be associated with some adverse consequences, such as the occurrence of acute psychotic episodes and the development of chronic schizophrenia in some people even after its use has terminated. Recent studies have produced controversy about whether cannabis in heavy use can cause irreversible brain damage, particularly to adolescents, and thus whether a chronic psychosis could be a result of brain changes caused by cannabis. SUMMARY: From the evidence that exists, it appears that the above view is unlikely and that cannabis may even have benign effects on brain structure, not producing deleterious damage. Its neurochemical interactions with the dopaminergic pathway, however, may, particularly in genetically vulnerable individuals, have adverse consequences.
Authors: Golfo K Tzilos; Christina B Cintron; Jonas B R Wood; Norah S Simpson; Ashley D Young; Harrison G Pope; Deborah A Yurgelun-Todd Journal: Am J Addict Date: 2005 Jan-Feb
Authors: Jennifer T Sneider; Harrison G Pope; Marisa M Silveri; Norah S Simpson; Staci A Gruber; Deborah A Yurgelun-Todd Journal: Exp Clin Psychopharmacol Date: 2006-11 Impact factor: 3.157
Authors: M T Lynskey; A C Heath; E C Nelson; K K Bucholz; P A F Madden; W S Slutske; D J Statham; N G Martin Journal: Psychol Med Date: 2002-02 Impact factor: 7.723
Authors: Marco Colizzi; Conrad Iyegbe; John Powell; Gianluca Ursini; Annamaria Porcelli; Aurora Bonvino; Paolo Taurisano; Raffaella Romano; Rita Masellis; Giuseppe Blasi; Craig Morgan; Katherine Aitchison; Valeria Mondelli; Sonija Luzi; Anna Kolliakou; Anthony David; Robin M Murray; Alessandro Bertolino; Marta Di Forti Journal: Schizophr Bull Date: 2015-03-31 Impact factor: 9.306
Authors: Murat Yücel; Emre Bora; Dan I Lubman; Nadia Solowij; Warrick J Brewer; Sue M Cotton; Philippe Conus; Michael J Takagi; Alex Fornito; Stephen J Wood; Patrick D McGorry; Christos Pantelis Journal: Schizophr Bull Date: 2010-07-25 Impact factor: 9.306
Authors: Berend Malchow; Alkomiet Hasan; Thomas Schneider-Axmann; Alexander Jatzko; Oliver Gruber; Andrea Schmitt; Peter Falkai; Thomas Wobrock Journal: Eur Arch Psychiatry Clin Neurosci Date: 2013-10-02 Impact factor: 5.270
Authors: Ariella A Camera; Veronica Tomaselli; Jerry Fleming; Gul A Jabbar; Melissa Trachtenberg; Juan A Galvez-Buccollini; Ashley C Proal; Richard N Rosenthal; Lynn E Delisi Journal: Harm Reduct J Date: 2012-03-30